Loading…
Employees: 247
Size Revenio (REG1V.HE) is a Finland Health Care company (Medical Specialties) with a market value of $494M, the 52nd largest of 65 Finland companies the cockpit tracks. Shares closed at €10.48 on 6 Nov 2026.
Performance Over six months the shares fell 21.6%, against -9.7% for the median peer and -2.9% for the Finland market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 15.6% over the last twelve months (peer median +0.3%); the operating margin is 14.2% (peer median 2.4%).
Valuation It trades at 18.5× forward earnings against a peer median of 18.3× (5th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.0 points below its cost of capital (6.6% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €124M | €110M | €104M | €96.6M | €97.0M |
| Revenue growth | — | +6% | +7% | 0% | — |
| Gross profit | €48.2M | €46.9M | €44.7M | €45.2M | €47.0M |
| EBITDA | €22.7M | €29.7M | €29.9M | €30.1M | €32.9M |
| Net income | €13.2M | €17.4M | €18.5M | €19.1M | €21.8M |
| Free cash flow | €11.8M | €29.1M | €22.7M | €10.2M | €22.1M |
| Capital expenditure | €4.78M | €4.18M | €4.17M | €4.08M | €2.00M |
| Total debt | €259M | €11.0M | €12.8M | €17.3M | €19.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | REG1V.HE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -4.6% | 10th highest of 21 |
| 6-month return | -21.6% | -9.7% | 5th lowest of 21 |
| Distance from 52-week high | -56.1% | -31.4% | 3rd lowest of 21 |
| Revenue growth (TTM) | +15.6% | +0.3% | 3rd highest of 21 |
| Operating margin | 14.2% | 2.4% | 3rd highest of 21 |
| Forward P/E | 18.5× | 18.3× | 5th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | 19.3% | 10.1% | 5th most demanding of 14 |
| Growth delivered (Del g) | +12.4% | +0.4% | 2nd highest of 14 |
| Hurdle (Req g minus delivered) | +6.9 pp | +6.4 pp | 6th most demanding of 14 |
| ROIC minus cost of capital | -3.0 pp | -5.3 pp | 9th highest of 19 |
| EV / EBITDA | 30.0× | 9.0× | most expensive of 5 |
| Net debt / EBITDA | 10.6× | -1.2× | most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 18.5× | 19.3% | +12.4% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | n/a | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 12.2× | -5.6% | +7.7% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | n/a | n/a | n/a |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | n/a | 10.1% | +120.2% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | n/a | 14.8% | -4.7% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 7.4× | -3.9% | -4.3% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | n/a | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 24.4× | 5.0% | +5.0% |